A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Latest Information Update: 05 Jun 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Etrumadenant (Primary) ; Hyaluronidase (Primary) ; Motixafortide (Primary) ; Selicrelumab (Primary) ; Simlukafusp alfa (Primary) ; Tiragolumab (Primary) ; Tocilizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Morpheus-Pancreatic Cancer; MORPHEUS-PDAC
- Sponsors Roche
- 05 Jun 2024 According to results presented at the 115th Annual Meeting of the American Association for Cancer Research, the ORR primary endpoint was not met although both median PFS and OS were numerically improved with the combination therapy of atezolizumab + etrumadenant + chemotherapy suggesting that the addition of etruma and atezo may confer a benefit.
- 08 May 2024 Results published in the Arcus Biosciences Media Release.
- 08 May 2024 According to an Arcus Biosciences media release, data from this study has been presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2024.